D P Cohen - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

D P Cohen

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.

Nature Genetics|January 13, 1998

Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadismL C Layman, D P Cohen, M Jin, et al.

European Journal of Cancer (Oxford, England : 1990)|March 14, 2009

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failureS George, J Y Blay, P G Casali, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2014

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS-H I Ou, P A Jänne, C H Bartlett, et al.

Nature Genetics|January 13, 1998

Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadismL C Layman, D P Cohen, M Jin, et al.

European Journal of Cancer (Oxford, England : 1990)|March 14, 2009

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failureS George, J Y Blay, P G Casali, et al.

Pageof 3